Renagel

Renagel. It is a phosphate-binding medication, specifically a non-absorbed polymer, used primarily to manage hyperphosphatemia in patients with chronic kidney disease who are on hemodialysis. The drug works by binding dietary phosphate in the gastrointestinal tract, preventing its absorption and thereby helping to control serum phosphate levels, which is crucial for preventing complications like renal osteodystrophy and cardiovascular calcification. Developed by Genzyme, it offered a metal- and calcium-free alternative to traditional phosphate binders like calcium acetate and aluminum hydroxide.

Medical uses

Renagel is indicated for the control of serum phosphorus in patients with chronic kidney disease on hemodialysis, as elevated phosphorus is a key factor in the development of mineral and bone disorder. It is used as part of a comprehensive treatment regimen that includes dietary phosphate restriction and adequate dialysis. The medication is particularly valuable for patients who cannot tolerate or have contraindications to calcium-based binders, such as those with hypercalcemia or vascular calcification. Clinical studies, including those published in the New England Journal of Medicine, have demonstrated its efficacy in lowering phosphate levels without affecting calcium.

Adverse effects

The most common adverse effects associated with Renagel are gastrointestinal in nature, including nausea, vomiting, dyspepsia, diarrhea, and abdominal pain. Serious but less common side effects can include intestinal obstruction, fecal impaction, and bowel perforation, particularly in patients with pre-existing gastrointestinal disorders like diverticulitis or inflammatory bowel disease. Unlike some older binders, it does not cause aluminum toxicity or hypercalcemia, but drug interactions, such as reduced absorption of concomitantly administered medications like levothyroxine and ciprofloxacin, require careful management. Post-marketing surveillance by the Food and Drug Administration continues to monitor its safety profile.

Pharmacology

Pharmacologically, Renagel is a cross-linked polymer of poly(allylamine hydrochloride) that is not absorbed from the gastrointestinal tract. It acts through ion-exchange and hydrogen binding, capturing dietary phosphate ions within the lumen of the gut and forming insoluble complexes that are excreted in the feces. Its mechanism is non-systemic, meaning it does not enter the bloodstream, which minimizes systemic side effects. The binding capacity is pH-dependent and occurs primarily in the small intestine. Pharmacokinetic studies show no measurable absorption, metabolism, or excretion by the kidneys or liver, making it suitable for patients with end-stage renal disease.

History

The development of Renagel (sevelamer hydrochloride) was driven by the need for a safer phosphate binder that avoided the risks of metal accumulation and calcium overload. Research and development were spearheaded by the biotechnology company Genzyme in the 1990s. It received approval from the Food and Drug Administration in the United States in 1998, following clinical trials that demonstrated its non-inferiority to existing therapies. Its introduction marked a significant advancement in nephrology, providing an alternative during a period of increased awareness of cardiovascular calcification risks. Later, a carbonate form, sevelamer carbonate, was also developed and marketed as Renvela.

Society and culture

Renagel had a substantial impact on the standard of care in nephrology and dialysis units worldwide, influencing clinical guidelines from organizations like the National Kidney Foundation through its Kidney Disease Outcomes Quality Initiative. Its high cost, however, has been a point of discussion in healthcare economics, especially within systems like the National Health Service in the United Kingdom. The drug has been involved in various clinical studies comparing it to other binders like lanthanum carbonate and ferric citrate. The brand name Renagel is owned by Sanofi, which acquired Genzyme, and it remains a widely recognized treatment in the management of chronic kidney disease.